SG Americas Securities’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $897K | Sell |
4,728
-3,285
| -41% | -$618K | ﹤0.01% | 1952 |
|
|
2026
Q1 | $1.58M | Sell |
8,013
-118,724
| -94% | -$22.9M | ﹤0.01% | 1506 |
|
|
2025
Q4 | $23.3M | Buy |
126,737
+103,731
| +451% | +$18.2M | 0.03% | 450 |
|
|
2025
Q3 | $3.53M | Buy |
23,006
+17,845
| +346% | +$2.7M | 0.01% | 647 |
|
|
2025
Q2 | $721K | Buy |
5,161
+2,853
| +124% | +$400K | ﹤0.01% | 1396 |
|
|
2025
Q1 | $339K | Sell |
2,308
-104,486
| -98% | -$15.1M | ﹤0.01% | 2106 |
|
|
2024
Q4 | $14M | Buy |
106,794
+98,386
| +1,170% | +$13.8M | 0.06% | 177 |
|
|
2024
Q3 | $1.31M | Sell |
8,408
-8,178
| -49% | -$1.32M | ﹤0.01% | 884 |
|
|
2024
Q2 | $2.59M | Buy |
16,586
+3,528
| +27% | +$531K | 0.02% | 834 |
|
|
2024
Q1 | $1.77M | Sell |
13,058
-6,697
| -34% | -$887K | 0.01% | 911 |
|
|
2023
Q4 | $2.66M | Sell |
19,755
-28,850
| -59% | -$3.75M | 0.02% | 561 |
|
|
2023
Q3 | $6.58M | Sell |
48,605
-5,139
| -10% | -$702K | 0.08% | 233 |
|
|
2023
Q2 | $7.69M | Sell |
53,744
-22,919
| -30% | -$3.37M | 0.06% | 235 |
|
|
2023
Q1 | $10.6M | Buy |
76,663
+51,143
| +200% | +$6.88M | 0.12% | 129 |
|
|
2022
Q4 | $3.46M | Sell |
25,520
-1,165
| -4% | -$146K | 0.04% | 367 |
|
|
2022
Q3 | $2.93M | Buy |
26,685
+5,352
| +25% | +$679K | 0.04% | 415 |
|
|
2022
Q2 | $2.82M | Sell |
21,333
-689
| -3% | -$90.4K | 0.03% | 560 |
|
|
2022
Q1 | $2.92M | Buy |
22,022
+5,486
| +33% | +$658K | 0.02% | 679 |
|
|
2021
Q4 | $1.93M | Sell |
16,536
-1,981
| -11% | -$233K | 0.01% | 1111 |
|
|
2021
Q3 | $2.22M | Sell |
18,517
-12,834
| -41% | -$1.49M | 0.01% | 1170 |
|
|
2021
Q2 | $3.76M | Sell |
31,351
-5,017
| -14% | -$550K | 0.02% | 743 |
|
|
2021
Q1 | $3.62M | Buy |
36,368
+29,883
| +461% | +$3M | 0.02% | 688 |
|
|
2020
Q4 | $648K | Buy |
6,485
+2,585
| +66% | +$274K | ﹤0.01% | 1794 |
|
|
2020
Q3 | $427K | Buy |
3,900
+2,061
| +112% | +$229K | ﹤0.01% | 1735 |
|
|
2020
Q2 | $194K | Sell |
1,839
-4,002
| -69% | -$413K | ﹤0.01% | 2880 |
|
|
2020
Q1 | $522K | Buy |
+5,841
| New | +$550K | ﹤0.01% | 1816 |
|
|
2019
Q4 | – | Sell |
-67,699
| Closed | -$6.04M | – | 3276 |
|
|
2019
Q3 | $6.04M | Buy |
67,699
+4,843
| +8% | +$420K | 0.05% | 395 |
|
|
2019
Q2 | $5.19M | Buy |
+62,856
| New | +$4.93M | 0.04% | 510 |
|
|
2019
Q1 | – | Sell |
-60,780
| Closed | -$4.62M | – | 3354 |
|
|
2018
Q4 | $4.62M | Buy |
+60,780
| New | +$4.75M | 0.04% | 421 |
|
|
2018
Q3 | – | Sell |
-72,420
| Closed | -$5.08M | – | 3136 |
|
|
2018
Q2 | $5.08M | Buy |
72,420
+57,459
| +384% | +$4.13M | 0.05% | 430 |
|
|
2018
Q1 | $1.05M | Buy |
+14,961
| New | +$1.04M | 0.01% | 1309 |
|
|
2017
Q4 | – | Sell |
-8,955
| Closed | -$607K | – | 3190 |
|
|
2017
Q3 | $607K | Sell |
8,955
-4,005
| -31% | -$253K | 0.01% | 1677 |
|
|
2017
Q2 | $884K | Buy |
12,960
+2,978
| +30% | +$194K | 0.01% | 1491 |
|
|
2017
Q1 | $622K | Buy |
9,982
+497
| +5% | +$28.9K | 0.01% | 1699 |
|
|
2016
Q4 | $518K | Buy |
+9,485
| New | +$539K | ﹤0.01% | 1676 |
|
Other funds holding AZN
EP
IA
SG Americas Securities's AZN Position: Q2 2026 in Review
SG Americas Securities reduced its AstraZeneca (AZN) stake by 41% in Q2 2026, selling an estimated $618K and leaving 4,728 shares worth $897K. The position accounts for ﹤0.01% of the portfolio, ranked #1952.
SG Americas Securities first reported a position in AZN in Q4 2016 and has held it in 35 quarters since. The position peaked at $23.3M in Q4 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- SG Americas Securities held 4,728 shares of AstraZeneca worth $897K as of Q2 2026.
- SG Americas Securities sold 3,285 AstraZeneca shares in Q2 2026, an estimated $618K.
- AstraZeneca made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1952 holding.
- SG Americas Securities first reported a position in AstraZeneca in Q4 2016 and has held it in 35 quarters since.
- SG Americas Securities's AstraZeneca position peaked at $23.3M in Q4 2025.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.